The Pittsburgh Scientific and Data Research Center for the COPE-AKI Consortium (Pitt-SDRC)
COPE-AKI 联盟匹兹堡科学与数据研究中心 (Pitt-SDRC)
基本信息
- 批准号:10451746
- 负责人:
- 金额:$ 73.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-19 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAcute Renal Failure with Renal Papillary NecrosisAddressAdverse eventAmbulatory CareBiometryCardiovascular systemCaringCessation of lifeChronic Kidney FailureClinical DataClinical TrialsClinical Trials DesignCollaborationsConduct Clinical TrialsConsensusContinuity of Patient CareDataData AnalysesData CollectionData Coordinating CenterDevelopmentDialysis procedureEducationEnd stage renal failureGillsGlucoseGoalsHealthHospitalizationHospitalsImpaired healthIncidenceInformation DisseminationInjury to KidneyInterventionKidneyKidney DiseasesKnowledgeLeadManualsMeasurementMedicalMedication ManagementMonitorMorbidity - disease rateNursesOnline SystemsOutcomes and Health Services ResearchParticipantPatient Outcomes AssessmentsPatient-Focused OutcomesPatientsPersonsPharmacistsPharmacologyPhasePopulationProceduresProcessProtocols documentationRandomizedRecording of previous eventsRecordsRecurrenceRenin-Angiotensin-Aldosterone SystemReportingResearchResearch DesignRiskRisk FactorsSafetySodiumSymptomsSyndromeSystemTechnologyTestingTimeUnited States National Institutes of HealthUniversitiesadverse outcomecardiovascular risk factorclinical centerclinically relevantdata disseminationdata managementdata qualitydesigndisabilityevidence baseexperiencefollow-uphealth managementhealth related quality of lifehigh riskhospital readmissionkidney dysfunctionmulti-component interventionmultidisciplinaryoperationpatient engagementpatient orientedprimary outcomeprocess optimizationprogramsprotocol developmentreadmission ratessatisfactionsuccesstelehealthtreatment as usualvirtual visit
项目摘要
ABSTRACT
Acute kidney injury (AKI) and chronic kidney disease (CKD) are “interconnected” syndromes in
which each influences the other. CKD is a risk factor for AKI and AKI contributes to the
development or progression of CKD, end-stage renal disease (ESRD), cardiovascular symptoms,
and death, not to mention recurrent AKI episodes and impaired health-related quality of life
(HRQoL). Processes of care after AKI hospitalization have been found to be suboptimal, with
lack of continuity of care, delayed follow-up and suboptimal medication management
exacerbating the risks of adverse outcomes. In addition, optimal pharmacologic therapy, such as
blockade of the renin-angiotensin-aldosterone system (RAAS) or sodium-glucose cotransporter
type 2 (SGLT2), has not been defined. The Caring for OutPatiEnts after Acute Kidney Injury
(COPE-AKI) Consortium will address these important gaps in knowledge of optimal
management of patients surviving an episode of moderate (stage 2) or severe (stage 3) AKI. The
goal of the COPE-AKI Consortium will be to develop and test interventions to optimize
processes of care and identify key pharmacologic and non-pharmacologic interventions to
reduce morbidity among these high-risk patients. The Center for Clinical Trials & Data
Coordination (CCDC) at the University of Pittsburgh is well poised to serve as the Scientific and
Data Research Center (SDRC) for the COPE-AKI Consortium. Our multidisciplinary
investigative team has a history of collaboration, wealth of experience and expertise, including
expertise in acute and chronic kidney disease, critical and translational care, medication
management, design of clinical trials, telehealth, clinical and data coordination, project
administration support, biostatistics, measurement of patient-reported outcomes, health
services research and patient engagement. Our goal is to serve as the Scientific and Data
Research Center for the COPE-AKI Consortium. Specifically, we will 1) establish an efficient and
rigorous process for designing the Consortium study, including protocol development and
adaptation of an existing web-based data collection system; 2) provide comprehensive expertise
for data management and analysis within the Consortium; and 3) provide program coordination
and administrative support throughout all phases of the study.
摘要
急性肾损伤(阿基)和慢性肾病(CKD)是“相互关联”的综合征,
它们相互影响。CKD是阿基的风险因素,阿基有助于
CKD、终末期肾病(ESRD)、心血管症状的发生或进展,
和死亡,更不用说复发性阿基发作和健康相关生活质量受损
(HRQoL)。阿基住院后的护理过程被发现是次优的,
护理缺乏连续性,后续行动延迟,药物管理欠佳
加剧了不良后果的风险。此外,最佳的药物治疗,如
阻断肾素-血管紧张素-醛固酮系统(RAAS)或钠-葡萄糖协同转运蛋白
2型(SGLT 2)尚未定义。门诊急性肾损伤患者的护理
(COPE-AKI)联盟将解决这些重要的知识差距,
管理中度(2期)或重度(3期)阿基发作后存活的患者。的
COPE-AKI联盟的目标是开发和测试干预措施,
护理过程,并确定关键的药物和非药物干预措施,
降低这些高危患者的发病率。临床试验和数据中心
匹兹堡大学的协调(CCDC)已经做好准备,
COPE-AKI联盟的数据研究中心(SDRC)。我们的多学科
调查小组有着合作的历史、丰富的经验和专业知识,包括
在急性和慢性肾脏疾病、重症和转化护理、药物治疗方面的专业知识
管理、临床试验设计、远程医疗、临床和数据协调、项目
管理支持,生物统计学,患者报告结局的测量,健康
服务研究和患者参与。我们的目标是作为科学和数据
COPE-AKI联盟的研究中心。具体而言,我们将1)建立一个有效的,
设计联盟研究的严格流程,包括方案制定和
调整现有的网络数据收集系统; 2)提供全面的专门知识
在联合体内进行数据管理和分析; 3)提供项目协调
在研究的所有阶段提供行政支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kaleab Z Abebe其他文献
Kaleab Z Abebe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kaleab Z Abebe', 18)}}的其他基金
(2/2) Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)
(2/2) 溴隐亭在围产期心肌病 (REBIRTH) 心肌恢复治疗中的随机评价
- 批准号:
10703436 - 财政年份:2021
- 资助金额:
$ 73.08万 - 项目类别:
The Pittsburgh Scientific and Data Research Center for the COPE-AKI Consortium (Pitt-SDRC)
COPE-AKI 联盟匹兹堡科学与数据研究中心 (Pitt-SDRC)
- 批准号:
10296801 - 财政年份:2021
- 资助金额:
$ 73.08万 - 项目类别:
(2/2) Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)
(2/2) 溴隐亭在围产期心肌病 (REBIRTH) 心肌恢复治疗中的随机评价
- 批准号:
10445019 - 财政年份:2021
- 资助金额:
$ 73.08万 - 项目类别:
The Pittsburgh Scientific and Data Research Center for the COPE-AKI Consortium (Pitt-SDRC)
COPE-AKI 联盟匹兹堡科学与数据研究中心 (Pitt-SDRC)
- 批准号:
10670114 - 财政年份:2021
- 资助金额:
$ 73.08万 - 项目类别:
(2/2) Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)
(2/2) 溴隐亭在围产期心肌病 (REBIRTH) 心肌恢复治疗中的随机评价
- 批准号:
10213992 - 财政年份:2021
- 资助金额:
$ 73.08万 - 项目类别:
Data Coordinating Center for the Halt-Polycystic Kidney Disease Trials
停止多囊肾病试验数据协调中心
- 批准号:
8658816 - 财政年份:2008
- 资助金额:
$ 73.08万 - 项目类别:














{{item.name}}会员




